Everybody is fat.
Altimmune's ALT-801 data 'impressive', says JMP Securities 06:29 ALT JMP Securities analyst Jonathan Wolleben keeps his price target on Altimmune at $31 along with his Outperform rating on the shares. The analyst writes that his recent discussion with an expert on GLP-1-based drug development indicated that he was very impressed with the six-week data for ALT-801 in June, calling it a "tremendous amount of weight loss" in a relatively short period of time. Wolleben adds that the expert also highlighted the "very good GI tolerability profile with no dose titration".
Tesla's Elon Musk reveals plans for humanoid robot, WSJ reports 06:26 TSLA Tesla CEO Elon Musk, during an event around AI on Thursday, said the company will build a robot in a human form that could perform repetitive tasks, with a prototype likely to be ready next year, The Wall Street Journal's Rebecca Elliott reports. "Tesla is much more than an electric-car company," Musk said.
Now when your Tesla crashes into an emergency vehicle and bursts into flame you do not get hurt your humanoid robot (comes with car) Stan gets hurt.